Listar por autor "Monfort, Jordi"

Mostrando ítems 1-3 de 3

    • Blood RNA sequencing reveals immunological processes associated with the response to abatacept in rheumatoid arthritis. 

      Julià, Antonio; López Lasanta, María; Gómez, Antonio; Sanmartí, Raimon; Marras, Carlos; Pina Salvador, José Manuel; Romero Yuste, Susana; Veiga Cabello, Raúl María; Navarro, Pilar; Moragues Pastor, Carme; Martínez Pardo, Silvia; De-Toro, Javier; Sánchez, Amalia; Cerda, Dacia; Prada, Alejandro; Erra, Alba; Monfort, Jordi; Urruticoechea-Arana, Ana; Palau, Núria; Lastra, Raquel M.; Tortosa, Raúl; Pluma Sanjurjo, Andrea; Marsal, Sara (BMJ Journals, 2019-05-27)

    • Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib 

      Hochberg, Marc C.; Martel-Pelletier, Johanne; Monfort, Jordi; Möller, Ingrid; Castillo, Juan Ramón; Arden, Nigel; Berenbaum, Francis; Blanco García, Francisco J; Conaghan, Philip G.; Domènech, Gema; Henrotin, Yves; Pap, Thomas; Richette, Pascal; Sawitze, Allen; Souich, Patrick du; Pelletier, Jean-Pierre (BMJ, 2015-01-14)
      [Abstract] Objectives. To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. Methods. Double-blind ...

    • Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy 

      Juliá, Antonio; López-Lasanta, María; Blanco García, Francisco J; Gómez, Antonio; Haro, Isabel; juan Más, Antonio; Erra, Alba; García-Vivar, María L.; Monfort, Jordi; Sánchez-Fernández, Simón; González, Isidoro; Alperi-López, Mercedes; Castellanos-Moreira, Raúl; Fernández-Nebro, Antonio; Díaz-Torné, César; Lastra, Raquel M.; Lladós, Jordi; Palau, Núria; Sanmartí, Raimon; Marsal, Sara (Springer, 2021-04-21)
      [Abstract] Background. Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50–60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients ...